Unnecessary drug regulations hiking Rx prices in USA: NCPA Study

8 March 2013

As drug coverage increases as a result of expanded health insurance and Medicaid coverage under the USA’s Affordable Care Act, unnecessary regulations will increase prescription drug costs, according to a new study from the National Center for Policy Analysis (NCPA).

"Sixty percent of all Americans take a prescription drug in any given year, and nearly all seniors do," said NCPA Senior Fellow Devon Herrick, adding: "Drug coverage is expanding rapidly and heightened regulatory scrutiny will prevent drug plans managers from holding down costs for consumers with programs such as creating exclusive networks and encouraging mail-order prescriptions."

Mr Herrick said there are many barriers, regulations and practices that restrict competitive bidding among drug plan stakeholders, noting the following:

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Biotechnology